Maurice Wilkins Centre announces new Clinical Associates programme
30 July 2018
New Zealand based practising clinicians who would like to engage with the centre are invited to join as Clinical Associates.
Lung cancer drug poised for global approval, says MWC investigator
11 December 2017
Dacomitinib, an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed in collaboration with Pfizer by researchers led by MWC Associate Investigator Dr. Jeff Smaill, has shown significant efficacy in the treatment of patients with non-small-...
Human clinical trials planned for new anti-cancer compound
23 April 2015
After a decade of discovery and research, two University of Auckland medical oncology researchers along with their dedicated teams have developed a new anti-cancer compound that will advance to human phase two clinical trials. The co-inventors of the compound TH-4000, Dr Ad...
Promising New Zealand compound selected as drug candidate for tuberculosis
17 September 2012
A New Zealand-designed compound that shows promise against treatment-resistance tuberculosis (TB) has been selected as a drug candidate by international non-profit drug developer the Global Alliance for TB Drug Development (TB Alliance).
Local cancer drug approved for first clinical trial in United States and New Zealand
30 August 2012
The US Food and Drug Administration (FDA) has granted approval for PR610, an anticancer “stealth” drug invented in New Zealand, to move forward to human clinical trials through its approval of an Investigational New Drug (IND) Application for the drug.
Second New Zealand anticancer “stealth” drug targeted for clinical development
4 August 2011
A second anticancer “stealth” drug designed by New Zealand scientists has been targeted for clinical development under a collaborative agreement between Proacta Incorporated (San Diego) and Yakult Honsha Co., Ltd. (Tokyo).
Compound designed in New Zealand starves cancer cells of glucose
4 August 2011
Scientists from the Auckland Cancer Society Research Centre (ACSRC) and Maurice Wilkins Centre for Molecular Biodiscovery have designed a new compound that starves certain cancer cells of glucose, depriving them of energy.
New Zealand cancer drug to commence clinical trials
13 June 2011
A novel cancer drug designed by scientists from The University of Auckland and Maurice Wilkins Centre for Molecular Biodiscovery, and licensed to university spin-out company Pathway Therapeutics, Inc., has received approval from the US Food and Drug Administration to enter c...